Drug Information
Drug General Information | Top | |||
---|---|---|---|---|
Drug ID |
D04VQH
|
|||
Former ID |
DIB005010
|
|||
Drug Name |
XEN-D0501
|
|||
Synonyms |
XEN-D501; Ion channel modulator 1 (overactive bladder), Xention; TRPV1 antagonist (overactive bladder), Xention;VR1 antagonist (overactive bladder), Xention; Vanilloid receptor-1 antagonist (overactive bladder), Xention; Ion channel modulator (overactive bladder), Xention/Scion/Bristol-Myers Squibb
Click to Show/Hide
|
|||
Indication | Overactive bladder [ICD-11: GC50.0; ICD-10: N32.8] | Phase 2 | [1] | |
Company |
Bristol-Myers Squibb Co
|
Target and Pathway | Top | |||
---|---|---|---|---|
Target(s) | Transient receptor potential cation channel V1 (TRPV1) | Target Info | Antagonist | [2] |
KEGG Pathway | Neuroactive ligand-receptor interaction | |||
Inflammatory mediator regulation of TRP channels | ||||
NetPath Pathway | IL2 Signaling Pathway | |||
Pathway Interaction Database | Trk receptor signaling mediated by the MAPK pathway | |||
Trk receptor signaling mediated by PI3K and PLC-gamma | ||||
Reactome | TRP channels |
References | Top | |||
---|---|---|---|---|
REF 1 | ClinicalTrials.gov (NCT02233699) A Study to Assess the Efficacy of XEN-D0501 in Reducing the Cough Frequency in Patients With Chronic Idiopathic Cough. U.S. National Institutes of Health. | |||
REF 2 | An investigation of the safety and pharmacokinetics of the novel TRPV1 antagonist XEN-D0501 in healthy subjects. Br J Clin Pharmacol. 2011 Dec;72(6):921-31. |
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.